Patent SG-11201909041S-A (SG)
Title: Anti-pd-l1 antibody and use thereof
Inventor: LAVROVSKY YAN
IPC: C12N15/13
Filed: 2018-04-18
Abstract: CMarotta' nub .45-1 AA.Phstrort • • 71 , Seri Eor Ege-551 5srscr chip OR cents W O 20 18/ 195 226 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT omits otiolom omullom mom° an (10) International Publication Number WO 2018/195226 Al (51) International Patent Classification: C07K 16/28 (2006.01) Cl 2N 15/13 (2006.01) C12N 15/63 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2018/028206 (22) International Filing Date: 18 April 2018 (18.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/US2017/028206 18 April 2017 (18.04.2017) US (71) Applicant: R-PHARM OVERSEAS, INC. [US/US]; 12526 High Bluff Dr. Ste 300, San Diego, CA 92130 (US). (72) Inventors: LAVROVSKY, Yan; 1969 Zapo Street, Del Mar, CA 92014 (US). XU, Ting; 67 Wayne Road, Need- ham, MA 02492 (US). BARBASHOV, Sergei; 31105 Quail Meadows, Irvine, CA 902603 (US). REPIK, Alex- ey; 3 Osenniy Boulevard, Apt. 106, Moscow, 121609 (RU). SAMSONOV, Mikhail; 74-6-77 Leningradsky Prospect, Moscow, 125313 (RU). IGNATIEV, Vasily; 13 Skolkovskoye Shosse, Apt. 212, Moscow, 121353 (RU). ARCHUADZE, Shorena; 19/2 Institutskaya Street, Apt.34, Mitischi, Moscow, 141002 (RU). (74) Agent: KORKHIN, Yakov, M.; SciTech Legal PC, PO Box 15696, Boston, MA 02215 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-PD-L1 ANTIBODY AND USE THEREOF (57) : Disclosed are fully human anti-PD-Ll antibodies and their corresponding applications. Fully human antibodies are capable of specifi- cally binding to human PD-L1. Antibodies were obtained by employing a yeast display library-based screening technique and also by affmity matura- M.,55.1 /OR dt tezatizurneb tion to further improve their affinity for PD-L1. The fully human anti-PD-Ll antibodies disclosed show good specificity, affmity and stability. They are capable of enhancing T cell activity by binding to activated T cells, while significantly inhibiting tumor growth. Disclosed fully human anti-PD-Ll an- tibodies can be used in the diagnosis and treatment of PD-Ll-related cancers and other associated diseases. Figure 17 [Continued on next page] WO 2018/195226 Al MIDEDIMONEMIEFIEDERIMIDEEMIEOHEVOIS Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))